JP2024546844A - ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態 - Google Patents

ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態 Download PDF

Info

Publication number
JP2024546844A
JP2024546844A JP2024535383A JP2024535383A JP2024546844A JP 2024546844 A JP2024546844 A JP 2024546844A JP 2024535383 A JP2024535383 A JP 2024535383A JP 2024535383 A JP2024535383 A JP 2024535383A JP 2024546844 A JP2024546844 A JP 2024546844A
Authority
JP
Japan
Prior art keywords
solid form
certain embodiments
degrees
solid
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546844A5 (https=
Inventor
イベット プルー－ラフランス キャロライン
ボルチコワ エリカ
シー．アメディオ ジュニア ジョン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2024546844A publication Critical patent/JP2024546844A/ja
Publication of JP2024546844A5 publication Critical patent/JP2024546844A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024535383A 2021-12-16 2022-12-16 ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態 Pending JP2024546844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
US63/290,136 2021-12-16
PCT/US2022/081795 WO2023114995A1 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2024546844A true JP2024546844A (ja) 2024-12-26
JP2024546844A5 JP2024546844A5 (https=) 2025-12-04

Family

ID=85172741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535383A Pending JP2024546844A (ja) 2021-12-16 2022-12-16 ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態

Country Status (11)

Country Link
US (2) US12012412B2 (https=)
EP (1) EP4448529A1 (https=)
JP (1) JP2024546844A (https=)
KR (1) KR20240119299A (https=)
CN (1) CN118401525A (https=)
AU (2) AU2022416644B2 (https=)
CA (1) CA3242577A1 (https=)
IL (1) IL313314A (https=)
MX (1) MX2024007517A (https=)
TW (1) TW202333676A (https=)
WO (1) WO2023114995A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012412B2 (en) * 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2024329573A1 (en) * 2023-08-22 2026-04-02 Cardurion Pharmaceuticals, Inc. Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RS52166B (sr) * 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
CN109893653A (zh) * 2017-12-11 2019-06-18 王慧敏 Pde9抑制剂的新用途
US12012412B2 (en) 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Also Published As

Publication number Publication date
MX2024007517A (es) 2024-08-19
AU2022416644A1 (en) 2024-07-04
NZ812114A (en) 2025-08-29
AU2025275149A1 (en) 2026-01-08
CA3242577A1 (en) 2023-06-22
KR20240119299A (ko) 2024-08-06
EP4448529A1 (en) 2024-10-23
TW202333676A (zh) 2023-09-01
CN118401525A (zh) 2024-07-26
IL313314A (en) 2024-08-01
US12012412B2 (en) 2024-06-18
US20230192707A1 (en) 2023-06-22
WO2023114995A1 (en) 2023-06-22
AU2022416644B2 (en) 2025-09-11
US20240300961A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
US20240083902A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2009235440B2 (en) Anhydrous crystal form of orvepitant maleate
AU2022283638B2 (en) Co-crystal forms of a novobiocin analog and proline
TWI820301B (zh) 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途
KR20210032428A (ko) 사이클로(-히스-프로)의 신규 다형 형태
WO2025149547A1 (en) New solid forms of n-[(1s,2e)-1-cyclopropyl-3-(methanesulfonyl)prop-2-en-1-yl]-2- (1,1-difluoroethyl)-4- phenoxypyrimidine-5-carboxamide
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
US20220251091A1 (en) Amorphous umbralisib monotosylate
HK40112450A (zh) 吡唑并[3，4-d]嘧啶化合物的固体形式
TW201908320A (zh) 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
US20190185482A1 (en) Morphic forms of marizomib and uses thereof
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
WO2026024591A1 (en) Tryptamine prodrug solid forms
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
CN112384221A (zh) 异喹啉酮的多晶态和非晶态形式及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251126